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ABSTRACT
Vitamin A, its physiological metabolites and synthetic derivatives (retinoids) have
been shown to have protective effects against the development of certain types of cancer.
In addition, pharmacological amounts of retinoids have been used with some success in
the treatment of a few human tumors. The chemoprevention effect of retinoids is most
likely exerted at the tumor promotion phase of carcinogenesis. Retinoids block tumor
promotion by either inhibiting proliferation, inducing apoptosis, inducing differentiation,
or a combination of these actions. Clinically, isotretinoin (13-cis-retinoic acid)
significantly decreases the incidence of second primary tumors in patients with head and
neck cancer and also reduces appearance of non-melanoma skin cancer in patients with
xeroderma pigmentosum. Retinoic acid has proven to be an effective treatment for
promyelocytic leukemia. However, retinoid resistance limits its use as a single agent.
Clinical trials are in progress to determine the efficiency of retinoids in treating other
types of cancer such as neuroblastoma and breast carcinoma. The development of
receptor-selective retinoids and selective inhibitors of retinoid metabolism may lead to
further use of retinoids in both chemoprevention and treatment of cancer.
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INTRODUCTION
The intention of this review is to discuss recent advances (within the last several
years) in our understanding of how retinoic acid, the major physiologically active
metabolite of vitamin A, functions as a chemo-preventative agent. Also I will review
data on recent clinical trials that have used retinoic acid or synthetic analogs as chemoprevention and therapeutic agents in selected human cancers. Readers seeking a more
comprehensive treatment of this and related fields are referred to the following reviews13

.
Vitamin A and its metabolites are vital for biological functions such as

embryogenesis, growth, differentiation, vision and reproduction4-8 . Early studies with
vitamin A-deficient animals revealed a connection between this vitamin and
susceptibility to carcinogenesis9,10. Subsequently, Lotan and others11-13 demonstrated that
many tumor cells grown in vitro had their proliferation significantly reduced by the
addition of retinoic acid to the culture medium. It was also found that retinoic acid could
restore “normal” functions (differentiation) to certain tumor cells such as
neuroblastoma14, melanoma15, and promyelocytic leukemia16. In the latter case, these
laboratory findings led to successful clinical trials such that use of retinoic acid is
standard treatment for promyelocytic leukemia. Insight into the mechanism by which
retinoic acid is able to reduce carcinogenesis in animals and to inhibit tumor cell growth
and/or induce differentiation in vitro took a major leap forward with the discovery of the
nuclear receptors in 1989 17, 18.
Our understanding of retinoic acid action has made great strides in the area of
control of gene expression, but progress in unraveling cellular retinoid metabolism and
nuclear transport has been slower. It appears that cellular retinol and retinoic acid
binding proteins act as transport proteins to move these retinoids to different cellular
locations where metabolism occurs19. Work by Chytil’s group20, suggested that cellular
retinoic acid binding protein could be found in the nucleus which implied that it may
affect gene function. This concept fell out of favor after the discovery of the nuclear
receptors. However, the use of a newer generation of antibodies has revealed that cellular
retinoic acid binding protein type II (CRABP II) is found in the nucleus and binds to both
RAR and RXR21. These data suggest that CRABP II may be the molecule which shuttles
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retinoic acid from its site of synthesis in the cytoplasm into the nucleus and delivers this
ligand to the nuclear receptors.
It is now well accepted that most if not all of the action of retinoic acid is due to
its ability to alter gene transcription. The relevant physiological form of the nuclear
receptors consist of an RAR and RXR heterodimer. RAR and RXR each have three
subtypes (α, β, and γ)22-24. Gene “knockout” experiments suggest that the RAR subtypes
are functionally redundant 25,26. However the interpretation of these findings has been
question and it was suggested that the experimental conditions create an artificial
redundancy 27. Knock out of RAR genes in F9 teratocarcinoma cells led to different
conclusions, i.e. that the different receptors control specific pathways of RA-induced
differentiation 28, 29. All of the RAR genes can generate isoforms by using alternate
promoters, alternate splicing and initiation of translation at an internal CUG codon30-34.
In contrast, among the RXR, only the RXRγ gene has been found to yield isoforms35.
Despite the expression of these isoforms in a tissue-specific fashion, it is not known
whether they regulate different sets of genes. RAR specifically binds all-trans retinoic
acid and 9-cis retinoic acid with almost equal affinity, while RXR only has high affinity
for binding 9-cis retinoic acid 36-38. RXR can also form heterodimers with other nuclear
receptors such as vitamin D3 and peroxisome proliferator-activated receptors39,40. A
major difference with these RXR partners is that ligand for either receptor can activate
transcription of the target gene41, while with RAR, ligand cannot bind to RXR due to
steric interference42. However, after RAR is activated by binding of retinoic acid, the
resultant conformational change allows RXR to bind its ligand. When both receptors in
the heterodimer bind ligand there is a synergistic increase in target gene transcription43.
Activity of the nuclear receptors is also regulated by co-repressors, which bind in the
absence of ligand, and co-activators, which only bind in the presence of ligand44,45. One
of the key co-activators is CBP/p300, which contains histone acetyl-transferase activity46.
By acetylating histones and “loosening” chromatin structure, this activator may allow
RXR/RAR access to target genes (Fig. 1). CBP/p300 is also required by many other
nuclear hormone receptors and transcription factors46-47 . Thus RAR activity may be
influenced by levels of these other receptors and transcription factors which compete with
RAR for the limited amount of CBP/p300 present in the cell’s nucleus.
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RETINOIDS AS CHEMOPREVENTATIVE AGENTS: MECHANISTIC AND
CLINICAL STUDIES

Retinoic acid is thought to act as an inhibitor of carcinogenesis by interfering with
promotion rather than initiation. Promotion can be blocked by a number of different
mechanisms, e.g. inhibition of proliferation, stimulation of differentiation, or induction of
apoptosis (Fig. 2). Most of the studies describing these effects have been performed on
tumor cells rather than pre-malignant cells. The underlying assumption is that the
mechanism for retinoid action will be similar in both cell types. However, what appears
to be emerging from these studies is that retinoic acid may achieve its physiological
effects through different pathways, depending on the origin of the cell type investigated
(e.g. skin vs. nerve).
Mechanistic Studies
Growth Arrest: In most sensitive cells, retinoic acid blocks cell cycle progression
somewhere in the G1 phase of the cycle. Thus investigators have explored the effect of
retinoic acid on cell cycle regulatory proteins. In human neuroblastoma cells which
arrest in G1 within two days of retinoid treatment, there was an increase in cyclindependent kinase (cdk) inhibitor p27kip1, but not in p21Waf1/cip1
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. This increase was

coincident with a decrease in cyclin-dependent kinase activity and an increase in G1
cyclin/kinase bound p27Kip1. This RA-induced cdk inhibitor may be crucial for retinoidinduced growth arrest in these neuroblastoma cells. In contrast to this study, a novel
mechanism for retinoic acid-induced growth arrest in immortalized human bronchial
epithelial cells was reported by Landenfeld, et al. 49. They found that retinoid-treated
cells had a marked decline in cyclin D1 protein (required for progression through G1),
but not mRNA. It was shown that this was due to enhanced ubiquitin-dependent
proteasome degradation of cyclin D1. The mechanism by which retinoic acid enhanced
this proteolysis remains unknown. A third potential mechanism for growth arrest was
reported by Teixeira and Pratt50. They found that in human breast cancer cells (MCF-7)
retinoic acid reduced the mRNA level of cyclin D1 and cdk 2, followed by a decrease in
their protein levels. The change was specific since there was no alteration in the mRNA
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or protein level of cdk 4 and cdc-2 (the mitotic cyclin-dependent protein kinase).
Extracts from retinoid-treated cells also contained a cdk 2-inhibitory activity. None of
these studies address the mechanism by which retinoic acid changes the level of cyclin,
cdk, or cdk inhibitor. From the time course data it appears unlikely that retinoic acid is
directly regulating the transcription of these genes. The challenge in the next few years
will be to elucidate the pathway which lead to the change in the expression of these
proteins.
apoptosis: In addition to inducing growth arrest, retinoic acid and various
retinoid analogs can also induce apoptosis in certain cell types. For example, retinoic
acid treatment causes apoptosis in human hepatoma cells51 and a variety of adult T-cell
leukemia cell lines52. In the hepatoma cells, retinoic acid up-regulated p21Waf1/Cip1, Bax
and cdc2 kinase as well as Rb2 and its phosphorylation. An inhibitor of cdc2 blocked the
activation of this kinase by retinoids and prevented retinoic acid-induced apoptosis.
Retinoic acid also increased the level of p21Waf1/Cip1 in the T-cell leukemia lines.
Activation of the Fas-Fas ligand system was not involved in retinoid-induced apoptosis.
Inhibition of azoxymethane-induced colon carcinogenesis by 9-cis-retinoic acid is
accompanied by apoptosis in the adenomas53. A synthetic retinoic N-(4hydroxylphenyl)retinamide (4-HPR) has chemo-preventative activity in animal models of
breast, bladder, lung, ovarian and prostate cancer54-56. It also has a much lower level of
deleterious side effects compared to retinoic acid55. However, there has been controversy
about the mechanism of action of 4-HPR. Oridate et. al. 57 reported that 4-HPR induced
apoptosis by the generation of reactive oxygen species (ROS). Recently, it has become
clear that 4-HPR can induce apoptosis by both increasing ROS and also by RARdependent mechanisms58,59. In addition, there may be other, as yet unidentified
pathways, by which 4-HPR can induce apoptosis60. Interestingly, retinoic acid has also
been shown to inhibit apoptosis in certain cells61. This finding raises caution about the
potential use of retinoic acid as a “universal” chemo-preventive agent for cancer.
differentiation: A third mechanism for the anti-carcinogenic action of retinoic
acid is its ability to induce differentiation. This would prevent an initiated cell from
being promoted into a tumor cell. In skin carcinogenesis dietary retinoic acid at
pharmacological concentrations had little effect on papilloma formation, but inhibited
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carcinoma incidence62. The mechanism by which retinoic acid can induce differentiation
is not yet known. Surprisingly, in some cells a sustained activation of the extracellular
signal-regulated (ERK) kinase is required for retinoids to induced differentiation63.
Usually this particular mitogen-activated kinase (MAP) is associated with growth factor
stimulation of cell proliferation64. The difference may be that growth factor stimulation
is transient, while retinoic acid treatment induces a sustained activation of the pathway.
There are also changes in the retinoic acid response system during carcinogenesis. Skin
tumor progression resulted in increased amounts of RXR and decreased amounts of
RAR65. Also in the conversion of premalignant oral lesions to head and neck cancer,
there is a high incidence of loss of RARβ expression66. Transfecting normal
keratinocytes with oncogenic ras induces a significant reduction in the expression of
RARα and γ receptors67. In light of these findings, there is emerging a viewpoint that
RAR may function as tumor suppressors.

Clinical Studies
aerodigestive tract: There have been a number of studies showing a statistically
significant inverse correlation between beta-carotene (dietary precursor to vitamin A)
intake and cancer risk.68,69. However in a component of the Physicians Health Study, a
12 year supplementation with beta-carotene or placebo showed no significant difference
between the groups with respect to incidence of specific tumors or the overall incidence
of malignancies70. In head and neck lesions, Hong et al. showed that pharmacological
administration of isotretinoin (13-cis-retinoic acid) resulted in regression of leukoplakia
(pre-malignant lesions)71. However, the lesions reappeared after the therapy was
discontinued. In a more recent study by Hong et al., high dose isoretinoin was found to
significantly decrease the incidence of second primary tumors in patients following
curative therapy of the initial primary tumor72. A clinical trial using N-4(ethoxycarbophenyl) retinamide found that cancer incidence among patients with severe
esophageal dysplasia was reduced by 43.2% compared to patients receiving placebo73.
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On the negative side the CARET study (beta-carotene, plus retinol) which included
smokers, former smokers, or workers exposed to asbestos was stopped 21 months earlier
than planned due to increased risk of lung cancer incidence and mortality in the treated
group74.
Skin: High dose isotretinoin reduced new skin cancer (non-melanoma) by 63% in
patients with xeroderma pigmentosum75. In contrast, treatment of patients previously
having basal cell carcinoma with low-dose isotretinoin did not produce a significant
difference in the occurrence of new basal cell carcinomas76. In a moderate risk group
(<10 actinic keratoses and no more than two prior skin cancers), treatment with retinol
had a significant reduction in the number of squamous, but not basal cell carcinomas77.
However, the same treatment regimen for a high risk group (history of four or more skin
cancers) did not reduce the incidence of either squamous or basal cell carcinoma78.
Cervix: Case-control and prospective studies have found an inverse correlation
between beta-carotene and presence of intraepithelial lesions in the cervix79. However,
there was no difference in progression rates of cervical intraepithelial neoplasms (CIN)
between patients given beta-carotene vs those given a placebo80. Meyskens et al81 treated
patients with grade 2 and 3 CIN with all-trans-retinoic acid. With grade 2 CIN, there was
complete histological regression of 43% of the treated group vs 27% in the placebo
group. No difference in regression rate was found between the two groups with stage 3
CIN (Table 1). These data are quite promising and together with the findings that
vitamin A and analogs inhibit human papilloma virus (HPV) - associated proliferation of
cervical epithelial cells suggest a place for retinoid therapy in inhibiting the progression
of early cervical lesions into cancer.
Breast: There have been observational studies suggesting that breast cancer risk
is lower in women having a high dietary intake of vitamin A82. Based on promising
animal studies with 4-HPR and breast cancer83, a five year study was initiated to
determine the efficacy of 4-HPR in reducing the incidence of contralateral breast cancer
in patients who had prior surgery for breast cancer. Preliminary results suggest an
inhibitory effect of 4-HPR on the occurrence of contralateral breast cancer among
premenopausal women84. Recent animals studies with a new retinoid analog (targretin)
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suggest that it is more effective than tamoxifen in preventing breast cancer and that it also
synergizes with tamoxifen for enhanced chemoprevention activity85.

RETINOIDS AS THERAPEUTIC AGENTS: MECHANISTIC AND CLINICAL
STUDIES

There are a plethora of studies showing that retinoic acid can inhibit the
proliferation and induce differentiation in a variety of human cell lines. Clinical trials to
determine the effectiveness of retinoids in treatment of cancer have yielded mixed results.
Remissions in patients with promyelocytic leukemia can induced by retinoic acid with a
high frequency. Also neuroblastoma has been shown to have some sensitivity to retinoic
acid. However, in many other solid tumors retinoids have minimal or no effect on tumor
growth or progression.

Mechanistic Studies
Leukemia: Acute promyelocytic leukemia is invariably associated with
chromosomal translocation of the RARα locus. In 99% of cases, RARα is fused to the
PML gene, which leads to the production of a chimeric protein86. PML is an interferoninducible gene that encodes a protein located in a discrete nuclear structure called PML
nuclear bodies87-89. Experiments with mice where the PML gene was inactivated by
homologous recombination revealed that PML regulates hemopoietic differentiation,
growth and tumorigenesis. These studies also showed that PML is a critical component
of the retinoic acid signal transduction pathway and its disruption via chromosomal
translocation may lead to development of acute promyelocytic leukemia. Retinoic acid
does not appear to have any substantial effect on the growth and differentiation of chronic
lymphocytic leukemia (CLL) or acute lymphocytic leukemia (ALL) either in vitro or in a
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clinical setting. In contrast, there are some indications that retinoic acid may have a place
in treatment of chronic myelogenous leukemia (CML), since it inhibits growth, induces
apoptosis and differentiation in CML-like cell lines90,91. Also retinoids have some
therapeutic effect especially when combined with other agents in clinical trails (see
below).

Neuroblastoma: Sidell first reported that retinoic acid induced growth arrest and
differentiation in a human neuroblastoma cell line92. Subsequent studies showed that a
variety of human and murine neuroblastoma cells were susceptible to retinoic acidinduced differentiation. Following the discovery of the naturally-occurring metabolite 9cis-retinoic acid it was shown that this retinoid had enhanced potency to induce
neuroblastoma differentiation as well as apoptosis93, 94. One of the characteristics of
neuroblastoma is its association with amplified/overexpressed N-myc gene especially in
more aggressive disease. Retinoic acid was found to decrease the expression of N-myc
and this was synergized by the addition of interferon γ to the cells95. Recently, insulinlike growth factor binding proteins (IGFBP) have been implicated in the effect of retinoic
acid on neuroblastoma differentiation. Retinoic acid increases the transcriptional rate of
the IGFBP-6 gene and reduced the transcription of the IGFBP-4 gene. This change in
expression correlates with the postulated roles of these IGFBPs in regulating the growth
of neuroblastoma cells96.

Breast Cancer: Retinoic acid inhibits mammary carcinogenesis in rodents and
inhibits proliferation of human breast cancer cells54, 97. Some insight into the mechanism
responsible for these actions was found when it was discovered that retinoic acid downregulates the expression of the progesterone receptor98.

The same study also found that

progestins can down-regulate the expression of RARα and γ mRNA. A further
relationship between steroids, their receptors and retinoic acid was uncovered by the
finding that the expression of RARα is markedly greater in ER+ vs ER- human breast
cancer cells. Estradiol was found to increase RARα, but not RARβ or γ expression in an
ER+ human breast cancer cell line99. These findings, i.e. loss of functional RARs, may
explain why ER+ human breast cancer cell lines are sensitive, while ER- lines are usually
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resistant to inhibition of proliferation induced by retinoic acid100. Some reports suggest
that RARα is the dominant retinoid receptor which mediates the effect of retinoic acid on
inhibition of breast cancer cell growth101, while other studies provide strong data that the
RARβ receptor mediates the effect of retinoic acid on growth and apoptosis in human
breast cancer cells102.
Investigators have found that overexpression of the c-erbB receptor tyrosine
kinase is linked to more aggressive forms of breast cancer103. Retinoic acid was found to
decrease the expression of c-erbB, specifically c-erbB-2 and 3 104. These results suggest
that retinoids might have a role in the treatment of more aggressive forms of breast
cancer. Also retinoic acid was shown to inhibit growth in human mammary epithelial
cells in which the tumor suppressor p53 was inactivated105. This is an important finding
since many tumors lack functional p53 and drugs that work through a pathway involving
this protein are ineffective in these particular tumors.

Clinical Studies
Promyelocytic Leukemia: Retinoic acid has been shown to induce remission with
high frequency in patients with acute promyelocytic leukemia (APL)106-108.
Unfortunately, the duration of remission is short (average of 6 months), due to acquisition
of resistance to retinoic acid (see below). Recent studies suggest that use of RARselective ligands may prolong remission and also reduce potential side effects of this
treatment109. The current standard therapy for APL involves a combination of retinoic
acid and chemotherapy. This regimen has resulted in complete remission rates of 90%
and has improved long term survival. There is intense interest in the mechanism of
retinoid resistance in APL patients. One possible mechanism is accelerated metabolism
of retinoic acid. One study reported that a decrease in plasma level of retinoic acid
during treatment of APL correlated with clinical recurrence. However, leukemic cells
from these patients remained sensitive to the differentiating effect of retinoic acid in
vitro110. Substituting 9-cis-retinoic acid for all-trans-retinoic acid did not result in
reversal of resistance despite little change in the plasma level of this retinoid111. Recent
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studies have examined the mechanism of retinoic acid-resistance in APL cell lines.
Mutations were found in the RARα receptor in several of these cell lines112. It appears
that this additional mutation in the PML/RARα gene blocks the induction of
differentiation by retinoic acid113. Similar mutations were found in cells from APL
patients exhibiting retinoic acid resistance113. Thus resistance to retinoid therapy might
have multiple mechanisms making it difficult to attack clinically. Other types of
leukemia have not been found to be sensitive to retinoic acid treatment, with the possible
exception of CML where some success has been achieved with a combination of retinoic
acid and interferon-α90. Also there is some evidence that lymphomas may be susceptible
to retinoid therapy114.

Solid Tumors: Although a variety of tumor cells are susceptible in vitro to growth
inhibition induced by retinoid acid, there has been limited success in the use of retinoids
to treat solid tumors (as opposed to chemoprevention). In a small sample of patients with
recurrent malignant glioma, there was partial/minor response to high-dose 13-cis-retinoic
acid in 23% of the group115. Although retinoids combined with interferon α inhibit
progression of early cervical lesions (see chemoprevention), this combination has little
effect on advanced cervical cancer116. In contrast, this drug combination appears to
improve oxygenation of cervical cancer and hence improve the percentage of responses
to radiotherapy117. There are several ongoing clinical trials of the effectiveness of
retinoids +/- other chemotherapeutic agents on inducing clinical responses in
neuroblastoma and breast cancer, but results have not yet been published.

CONCLUSIONS
Results of basic investigations suggest that retinoic acid acts as a
chemopreventive agent by inducing differentiation, growth arrest, apoptosis, or a
combination of these events. These effects are also responsible for its anti-tumor activity.
The pathway(s) by which retinoic acid achieves these effects is still poorly understood.
Based on results of clinical trials, it appears that retinoids may have a significant role in
the chemoprevention of head and neck, breast, cervical, and some types of skin cancers.
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In contrast the only proven effective therapeutic use of retinoids is in the treatment of
promyelocytic leukemia. However, the development of receptor-selective retinoids,
selective inhibitors of retinoid metabolism and increased understanding of the mechanism
of retinoid action may lead to an expanded use of retinoids as therapeutic agents for
various forms of cancer.
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Figure Legends

Fig. 1. Schematic diagram of the assembly of a transcriptionally active RXR:RAR
complex on target genes.
A. Inactive RXR:RAR complex bound to co-repressor. The RXR ligand binding
site is sterically blocked by RAR. Co-repressor has histone deacetylase activity
which keeps the chromatin in the “condensed” state. B. Assembly of active
complex. Addition of the ligand all-trans-retinoic acid, delivered to the nucleus
by CRABP II, induces a conformational change in RAR. As a result of the
change, the co-repressor is released, the RXR is free to bind its ligand 9-cisretinoic acid, and coactivators such as CBP/p300, pCAF and others (e.g. steroid
coactivator-1 (SRC-1)) bind to the RXR and RAR. CBP/p300 and pCAF have
histone acetyltransferase activity which induces a “loose” state of chromatin
structure required for active gene transcription.

Fig. 2. Mechanism by which retinoic acid inhibits tumor formation.
This diagram shows an initiated cell (carcinogen-induced mutation) being
promoted to a small foci of abnormal cells. In the absence of retinoic acid, these
abnormal cells can progress to a clinical tumor. When retinoic acid is present, it
can either arrest any further growth of the abnormal cells; induce the abnormal
cells to differentiate back to their normal counterparts, or induce the abnormal
cells to undergo apoptosis. The apoptotic (dead) cells are then ingested by
macrophages.
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Table 1. The degree of cervical dysplasia affects the ability of retinoic acid to induce
regression of CIN lesions.
Number of patients
with moderate
dysplasia

Regression of lesion
with placebo

Regression of lesion
with retinoic acid

151

27%

43%

31%

25%

Number of patients
with severe dysplasia
150

Data are from a randomized phase III trial conducted by Meyskens and Manetta81
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